
    
      Our group has developed a novel anti-ILT3 CAR T cell therapy, and this pilot study is focused
      on the safety and efficacy of the anti-ILT3 CAR-T for R/R AML(M4/M5) patients. A total of 25
      subjects are intravenously adminstered with anti-ILT3 CAR-T cells. The dosages of CAR-T cells
      follow the "3+3" dose increment program.
    
  